NDA 219910 · Glaukos
Epioxa Hd/Epioxa Kit
Riboflavin 5'-Phosphate Sodium · Ophthalmic
OrphanLast checked: Nov 19, 2026Latest source record: Oct 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Oct 17, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
35
10 Phase 3, 2 recruiting
FAERS reports
6
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 18, 2025.
EPIOXA HD and EPIOXA are indicated in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O 2 n System and the Boost Goggles. EPIOXA HD and EPIOXA are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O 2 n System and the Boost Goggles ( 1 ).
Mechanism: Riboflavin 5'-phosphate sodium (Vitamin B2) is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. Under the conditions used for corneal collagen cross-linking, riboflavin 5'-phosphate functions as a photoenhancer and generates singlet oxygen which is responsible for the cross-linking.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EPIOXA HD/EPIOXA KIT · RIBOFLAVIN 5'-PHOSPHATE SODIUM EQ 0.239% BASE/ML · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Riboflavin 5'-" as an intervention, any sponsor and status, largest first.
- Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria ComponentPivotal-lookingCompleted
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT00680732 · 1,370 participants · Start Jun 2003 · Primary completion Oct 2006
Drug: Chloroquine (CQ); Sulphadoxyne-pyrimethamine (SP) · For: Malaria; Malaria in Pregnancy
Sites: Bobo-Dioulasso, Burkina Faso
- Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic DisordersPivotal-lookingStatus unknown
Center for Sight, Sacramento, CAAcademic, hospital or other
NCT03858036 · 550 participants (planned) · Start Mar 8, 2019 · Primary completion Dec 31, 2024
Drug: Ricrolin+ · For: Keratoconus; Ectasia
Sites: Sacramento, California
- Corneal Crosslinking in Patients With Keratoconus and Post-Refractive EctasiaPivotal-lookingCompleted
Price Vision GroupIndustry
NCT01143389 · 510 participants · Start May 2010 · Primary completion May 30, 2017
Drug: Riboflavin · For: Keratoconus; Post-Refractive Ectasia
Sites: Indianapolis, Indiana
- Corneal Cross-Linking Comparing VariablesPivotal-lookingStatus unknown
Crowd Health Research, LTDAcademic, hospital or other
NCT02095730 · 500 participants (planned) · Start May 2014 · Primary completion May 2016
Drug: Epithelium-On Riboflavin; Epithelium-Off Riboflavin · For: Unstable Corneas
Sites: Santa Rosa, California; Denver, Colorado; Jacksonville, Florida · 16 sites in all
- Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial DysfunctionPivotal-lookingStatus unknown
Reven Pharmaceuticals, Inc.Industry
NCT03041259 · 320 participants (planned) · Start Jan 2020 · Primary completion Jan 2022
Drug: Rejuveinix Low Dose; Rejuveinix High Dose · For: Critical Limb Ischemia; Peripheral Arterial Disease
Nvision Laser Eye CentersIndustry
NCT02762253 · 320 participants · Start Sep 2012 · Primary completion Apr 2016
Drug: Riboflavin drops · For: Keratoconus
Sites: Camarillo, California; Citrus Heights, California; Fullerton, California · 11 sites in all
- Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)Pivotal-lookingStatus unknown
María de los Ángeles Tena PajueloAcademic, hospital or other
NCT04179604 · 300 participants (planned) · Start Jun 17, 2020 · Primary completion Jan 2022
Drug: Levosimendan; Placebos · For: Cardiac Output, Low
Sites: Badalona, Spain; Girona, Spain; Las Palmas de Gran Canaria, Spain · 9 sites in all
- Steroids and Cross-linking for Ulcer TreatmentPivotal-lookingCompleted
Thomas M. LietmanAcademic, hospital or other
NCT04097730 · 280 participants · Start Sep 24, 2020 · Primary completion May 18, 2024
Drug: Moxifloxacin Ophthalmic; Difluprednate Ophthalmic and 1 more · For: Keratitis Bacterial
Sites: San Francisco, California; Miami, Florida; Madurai, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- corneal epithelium defect5
- foreign body sensation in eyes1
- photophobia1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial.
Godfrey KM, Titcombe P, El-Heis S, et al. · PLoS Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Assessment of dispersion of airborne particles of oral/nasal fluid by high flow nasal cannula therapy.
Jermy MC, Spence CJT, Kirton R, et al. · PLoS One 2021 · Clinical Trial, Research Support, Non-U.S. Gov't
- Effects of riboflavin in the treatment of brain damage caused by oxygen deprivation: an integrative systematic review.
Silva-Araújo ERD, Manhães-de-Castro R, Pontes PB, et al. · Nutr Neurosci 2024 · Systematic Review
- A 2-Year Randomized Controlled Trial With Low-Dose B-Vitamin Supplementation Shows Benefits on Bone Mineral Density in Adults With Lower B12 Status.
Clements M, Heffernan M, Ward M, et al. · J Bone Miner Res 2022 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour.
Bostom AG, Jacques PF, Liaugaudas G, et al. · Arterioscler Thromb Vasc Biol 2002 · Clinical Trial, Randomized Controlled Trial
- Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension.
Chan P, Huang TY, Chen YJ, et al. · J Clin Pharmacol 1998 · Clinical Trial, Randomized Controlled Trial
Sponsor: Glaukos
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.